Hone Health Review: Is TRT a Longevity Plan?

The one-sentence version

Hone Health is the most price-transparent provider on our board and one of the least evidence-honest. Every medication it sells carries a published monthly figure, both membership tiers are posted, and the site states plainly: "No commitments. Cancel anytime." We found no hidden quarterly prepay, no introductory rate that expires, no consult-to-learn-pricing wall. That is genuinely rare, and it is worth crediting loudly. What Hone then does with that clarity is file testosterone and hormone replacement under "longevity" — a framing that the FDA-approved testosterone label explicitly declines to support, and that the largest randomised trials of testosterone in middle-aged and older men do not bear out. Buy it for what it is: a well-run, honestly-priced hormone clinic. Do not buy the healthspan story bolted onto the front of it. For the map of what is actually proven in this field, start with longevity medicine: what's proven vs hyped.

What Hone Health is, and who it's for

Hone is a telehealth hormone-optimization platform, sold in two tracks — a men's track built around testosterone replacement therapy (TRT), and a women's track built around menopause and hormone replacement — with a "longevity" shelf sitting alongside both. Corporately, care is delivered through independent practices: the site states that "Hone-affiliated medical practices are independently owned and operated by licensed physicians who provide services using the Hone telehealth platform," with physician recruitment run through a partnership with Broad Health.

The flow is lab-first and gated, in that order:

1. 1.Buy the biomarker test — $65. Hone describes it as "in-depth, 50-biomarker blood testing" plus health history and validated questionnaires. You either go to a partner lab or, where available, Hone sends a phlebotomist to you at no extra charge.
2. 2.Take a telehealth consult with a licensed physician, included in that $65.
3. 3.Pick a membership, then buy medication on top of it.

Nothing is prescribed before the labs exist. That gate is a genuine strength and the opposite of a rubber-stamp questionnaire — a distinction our grading methodology weights at 25%.

What it actually costs — and the tier that isn't the tier

All figures verified on honehealth.com in July 2026.

Entry: $65 for the 50-biomarker panel plus the physician consult and a plan. Hone calls this "100% risk-free."

Basic membership: $25/month, "plus cost of medication." What that buys, in Hone's own words: key biomarkers re-tested every 6 months, "the ability to purchase telehealth consults with expert licensed physicians," and "members-only pricing on BASIC medications & supplements."

Read that middle clause again. On the $25 tier, physician consults are not included — they are a separate purchase, and Hone does not publish what one costs. That is the single gap in an otherwise exemplary pricing page, and it matters, because a hormone protocol without follow-up consultation is not a protocol.

Premium membership: $155/month, "plus cost of medication." This includes the consults, the personalised protocol (testosterone, estrogen, weight loss), and "retesting + follow-ups every 90 days." Hone's own page labels this tier "Chosen by 95% of patients."

That last line is the honest headline. If 95% of buyers land on Premium, the real price of Hone is $155/month, not $25 — and a review that quotes the $25 figure as the price of entry is quoting a tier almost nobody uses. To Hone's credit, it publishes the 95% figure itself rather than hiding behind the cheap tier.

Medication is billed separately, and every drug is priced. On the men's TRT page: testosterone injections from $28/mo, testosterone cream from $60/mo, troches from $60/mo, clomiphene citrate from $38/mo, enclomiphene from $42/mo, anastrozole $22/mo — each stated as "+ membership." On the women's menopause page: estradiol patch $58/mo, bi-est cream $80/mo, progesterone $49/mo, progesterone cream $79/mo, Estrace estradiol cream $40/mo, Vagifem $65/mo, DHEA cream $56/mo, estriol vaginal cream $58/mo. On the longevity shelf: NAD+ $165/mo, glutathione $90/mo, vitamin B12 $60/mo, low-dose naltrexone $38/mo, metformin $25/mo, omega-3-acid ethyl esters $20/mo.

So the real all-in number, for the typical buyer: $65 to start, plus $155/month Premium, plus $28/month for testosterone injections — about $2,260 in the first year, and about $2,196 a year thereafter. That is a real, buildable figure you can compute before entering a card number, which is more than most of this category permits. Compare it against the price bands in how much a longevity clinic costs.

And the commitment check comes back clean. Hone states "No commitments. Cancel anytime." We found no product page where the advertised rate depended on a 3-, 6- or 12-month prepay. That is not the norm — the AgelessRx review documents a competitor whose headline prices are quarterly-plan and, in one case, introductory rates — and Hone deserves the contrast drawn in its favour.

What's included, what's extra

Included at Premium: quarterly retesting, physician consults and follow-ups, the personalised protocol, and members-only medication pricing.

Extra, always: the medication itself, on every tier. The membership fee buys the medical relationship, not the drug.

Extra on Basic: the consults. Price not published — the one figure Hone withholds.

Not offered: imaging, epigenetic-age testing, or the broad screening panel a diagnostics-led program provides. Hone's 50 markers are hormone-weighted by design, and are not a substitute for the outcome-validated core we describe in what longevity biomarker panels actually test.

Clinical oversight: who prescribes, and what they check

Structurally, this is good. Labs come before prescriptions. Premium members are retested every 90 days, which is the correct cadence for anyone on exogenous hormones — testosterone therapy requires periodic haematocrit, PSA and blood-pressure monitoring, and a quarterly rhythm supports that.

Two deductions. First, Hone names no physicians. Its physicians page describes affiliated practices in the abstract and lists no individual clinicians, credentials or board certifications, and no medical director is identified. A competitor like AgelessRx names its medical director and prescribers; Hone does not. Second, the Basic tier decouples oversight from the membership. A patient on $25/month with a testosterone prescription and no purchased consult is a patient on hormones without scheduled clinician contact — a configuration the platform permits.

The evidence behind what it sells

This is where the grade is decided, and where Hone's marketing outruns its data.

Testosterone, on the FDA label. Testosterone cypionate is approved "for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone" — specifically primary hypogonadism and hypogonadotropic hypogonadism. The label then carries an explicit Limitation of Use: "Safety and efficacy of testosterone cypionate in men with 'age-related hypogonadism' (also referred to as 'late-onset hypogonadism') have not been established." It also warns that "Testosterone can increase blood pressure which can increase cardiovascular (CV) risk over time," and notes that "Some studies, but not all, have reported an increased risk of MACE in association with use of testosterone replacement therapy"¹. Age-related low testosterone — the exact demographic a direct-to-consumer TRT platform serves — is the one indication the label declines to endorse.

What the big trials found. TRAVERSE randomised 5,246 men with hypogonadism and cardiovascular disease or high risk to testosterone or placebo; over a mean 33 months of follow-up, testosterone was noninferior to placebo for major adverse cardiac events (7.0% vs 7.3%; HR 0.96). That is reassuring — but the same trial found "a higher incidence of atrial fibrillation, of acute kidney injury, and of pulmonary embolism" in the testosterone group². The fracture substudy is the more striking result: after a median 3.19 years, clinical fractures occurred in 3.50% on testosterone versus 2.46% on placebo (HR 1.43, 95% CI 1.04–1.97), and the authors concluded that fracture incidence "was numerically higher among men who received testosterone"³. A therapy marketed for strength and vitality did not reduce fractures; it was associated with more of them.

What testosterone does do. The Testosterone Trials — 790 men aged 65+ with testosterone under 275 ng/dL and symptoms — found significantly increased sexual activity, desire and erectile function, a modest walking-distance benefit when all three trials were pooled, and no significant benefit for vitality⁴. That is a real but narrow effect on sexual function in genuinely low, genuinely symptomatic men. It is not a longevity result, and nothing in the trial measured lifespan.

The diagnostic bar. The Endocrine Society guideline recommends diagnosing hypogonadism "only in men with symptoms and signs consistent with testosterone deficiency and unequivocally and consistently low serum T concentrations," confirmed by repeating a fasting morning total testosterone measurement⁵. A single at-home draw is a screen, not a diagnosis. If Hone's protocol repeats the morning measurement before prescribing, that is worth knowing; the public pages do not say.

The women's track. Menopausal hormone therapy for vasomotor symptoms is legitimate, well-established medicine — that is not in dispute. What is in dispute is calling it longevity care. The Women's Health Initiative stopped its estrogen-plus-progestin arm early after a mean 5.2 years because the global index showed risks exceeding benefits: CHD HR 1.29, invasive breast cancer 1.26, stroke 1.41 and pulmonary embolism 2.13, against reductions in colorectal cancer (0.63) and hip fracture (0.66)⁶. WHI tested conjugated equine estrogens plus medroxyprogesterone acetate in women averaging 63, so it does not directly indict transdermal estradiol and micronised progesterone started near the menopausal transition — the products Hone actually sells. But it is precisely why "hormones extend healthspan" is not a claim anyone gets to assert casually.

The longevity shelf, claim by claim. Hone's own longevity page states that NAD+ "may increase lifespan, boost strength and physical performance, help with weight loss," and that metformin "promotes healthy aging and longevity." Neither survives contact with the human data. Oral nicotinamide riboside reliably raises NAD+ and is well tolerated⁷, but the strongest human trial to date improved 6-minute walk distance by roughly 17.6 metres in 90 people with peripheral artery disease, with the authors calling for a larger confirmatory trial⁸ — a disease endpoint, not a lifespan one. And Hone charges $165/month for it, the most expensive item on its longevity shelf and the one with the weakest support; our full read is in NAD+ for longevity. Metformin's longevity case is observational — better adjusted survival in metformin-treated diabetics versus matched non-diabetic controls in a UK database⁹ — and is offset by a randomised trial in which metformin blunted the gains from aerobic training in older adults, attenuating improvements in insulin sensitivity and VO₂ max¹⁰. See metformin for longevity.

Where it's weak

1. "Longevity" is doing work the evidence doesn't support. Hone's own copy asserts that NAD+ may increase lifespan and metformin promotes longevity, and files testosterone under healthspan. On our rubric, evidence honesty carries the heaviest weight (30%) precisely because overselling mechanism as outcome is the field's dominant failure mode — and this is a textbook case.

2. No named clinicians. For a platform whose entire value is the medical relationship, an anonymous prescriber roster is a real gap.

3. The $25 tier is close to a decoy. It excludes the consults, does not publish their price, and by Hone's own admission is chosen by 5% of patients. Quoting "$25/month" as Hone's price — as much of the internet does — is quoting a tier almost nobody buys.

4. Vertical dispensing. Hone tests you, interprets the result, prescribes, and sells the drug. That is common in telehealth and not disqualifying, but it raises the bar on the claims — and the claims are where Hone falls short.

5. The panel is hormone-weighted. Fifty markers sounds broad, but the tilt is toward the sex-hormone axis. If your goal is the cheap, outcome-validated core, a broad DTC panel does it better; see best longevity blood test services.

6. The biggest levers aren't on the panel at all. Cardiorespiratory fitness is among the most powerful survival predictors ever measured¹¹, and grip strength outpredicted systolic blood pressure across 17 countries in the PURE study¹². Neither is a hormone, and neither is billed monthly. See VO₂ max and longevity and grip strength and longevity.

Who should skip it

• •Anyone buying TRT as an anti-aging intervention. The FDA label declines to endorse it for age-related low testosterone, TRAVERSE found more atrial fibrillation, pulmonary embolism and acute kidney injury, and the fracture substudy found more fractures on testosterone than placebo.
• •Anyone whose testosterone is normal. A number in range plus fatigue is not hypogonadism, and the Endocrine Society bar is symptoms plus unequivocally low, repeated morning measurements.
• •Anyone comparing on the $25 tier. Without a purchased consult it is a monitoring subscription, not care.
• •Anyone buying NAD+ at $165/month. That is the priciest item on Hone's shelf, sold on a claim ("may increase lifespan") that no human trial supports.
• •Anyone who wants broad diagnostics. A hormone-weighted 50-marker panel is not a comprehensive workup — a lab membership does that job better, as we cover in longevity clinics vs lab memberships.

How it compares to the rest of our board

Against **AgelessRx**, the two fail in mirror-image ways. AgelessRx charges no membership and imposes no lab gate — structurally the better deal — but advertises "Starting at $X" floors whose billing terms are largely undisclosed, and on rapamycin publishes no month-to-month price at all. Hone gates everything behind a $65 test and a monthly fee, then prices every single drug in plain sight with no commitment. Pick Hone if knowing the bill in advance matters most; pick AgelessRx if avoiding a membership matters most — and note that AgelessRx's menu is longevity-first while Hone's is hormone-first.

Against **Lifeforce** — $349 starter plus $129/month — Hone is cheaper to enter ($65 vs $349) and slightly dearer to run at Premium, with a similar hormone tilt and a similar own-products conflict. The two are close substitutes; Hone's per-drug price list is the cleaner of the two.

Against a pure lab membership like **Function Health**, the difference is treat-versus-test: Function surfaces 100+ markers and hands you off, Hone runs a narrower panel and prescribes off it. Hone is the more useful product if you actually need a prescription, and the worse one if you want breadth.

The full graded field sits at our longevity provider rankings.

The grade, against our rubric

• •Clinical oversight (25%) — adequate. Labs precede prescriptions and Premium retests every 90 days, which is the right cadence for hormone therapy. Docked hard for naming no physicians and for a tier that lets a patient hold a hormone prescription with no included clinician contact.
• •Evidence honesty (30%) — weak. The decisive axis. "NAD+ may increase lifespan," "metformin promotes healthy aging and longevity," and TRT filed under healthspan are all claims running ahead of the human data, and the FDA label specifically declines the age-related indication.
• •Transparency (20%) — strong. Both tiers published, every drug priced, "No commitments. Cancel anytime," and the 95%-choose-Premium figure disclosed by Hone itself. Only the Basic-tier consult price is missing. Best-in-band.
• •Price-to-value (15%) — adequate. About $2,260 in year one for Premium plus testosterone injections is competitive against a bricks-and-mortar hormone clinic — and expensive if what you needed was a repeat morning testosterone draw and a conversation.
• •Conflicts of interest (10%) — mixed. Tests, interprets, prescribes and dispenses. Disclosed by structure, but it is the reason the marketing claims deserve scrutiny.

That lands a B−. Hone is a competently run, unusually honest-about-money hormone platform wearing a longevity costume. Strip the costume off and the underlying service is fine; leave it on and you are paying a healthspan premium for a symptom treatment.

Bottom line

Hone Health does the thing this site was built to reward: it publishes what everything costs. Both membership tiers, every medication, the entry price, and an explicit "No commitments. Cancel anytime" — we went looking for a quarterly prepay or an expiring introductory rate and did not find one. Only the Basic tier's consult price is withheld, and Hone even discloses that 95% of its patients choose the $155 tier rather than letting the $25 headline do the work.

What it does badly is the claim. Testosterone's own FDA label states that safety and efficacy in age-related hypogonadism have not been established; TRAVERSE found more atrial fibrillation, pulmonary embolism and acute kidney injury on treatment, and its fracture substudy found more fractures, not fewer; the Testosterone Trials found a real sexual-function benefit and no vitality benefit. Add "NAD+ may increase lifespan" at $165/month and "metformin promotes longevity" at $25/month and you have a pricing page we would hold up as a model attached to an evidence page we would not.

Buy Hone if you have symptoms and genuinely low, repeatedly-confirmed hormone levels, and you want that treated by a telehealth service that will tell you the bill in advance. Skip it if you are buying the healthspan story — and put the money into the two levers that outpredict almost every blood marker and are not for sale on any membership tier. Our full graded field is at our longevity provider rankings.